NRX Pharmaceuticals (NRXP) EBT (2017 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly EBT came in at -$5.0 million in Q1 2026, down 29.33% year-on-year from -$7.0 million in Q1 2025, and down 7.58% on a QoQ basis from -$4.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) EBT (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 10 years of EBT data on file, last reported at -$5.0 million in Q1 2026.
- On a quarterly basis, EBT fell 29.33% year-over-year to -$5.0 million in Q1 2026; TTM through Mar 2026 was -$17.5 million, a 7.34% decrease from a year earlier, with the FY2025 full-year figure at -$67.4 million, up 1.04% from the prior year.
- EBT for Q1 2026 stood at -$5.0 million, down from -$4.6 million in the prior quarter.
- Over the last five years, EBT for NRXP reached as high as -$2.4 million in Q4 2024 and fell as low as -$16.7 million in Q1 2022.
- Historically, EBT has averaged -$6.5 million across 5 years, with a median of -$5.0 million in 2026.
- Across the five-year window, EBT slumped 8190.75% in 2022 and soared 76.26% in 2023, its largest moves.
- Year by year, EBT stood at -$12.3 million in 2022, then jumped by 64.15% to -$4.4 million in 2023, then jumped by 44.97% to -$2.4 million in 2024, then sank by 90.28% to -$4.6 million in 2025, then fell by 7.58% to -$5.0 million in 2026.
- Per Business Quant data, the three most recent EBT figures were -$5.0 million in Q1 2026, -$4.6 million in Q4 2025, and -$4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 221.65 Mn |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 | -4.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Sep 30, 2025 | -4.21 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | -3.84 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Mar 31, 2024 | -6.35 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -6.19 Mn |
| Jun 30, 2023 | -8.09 Mn |
| Mar 31, 2023 | -3.97 Mn |
| Dec 31, 2022 | -12.31 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -9.75 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -37.05 Mn |
| Jun 30, 2021 | -117,613.00 |